Viewing Study NCT05271318

Home

Certify Doc

Genes

Clinical Trials

CompTox

DrugMatrix

Open Targets

Products

Support

Bugs

Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug

Ignite Creation Date: 2025-12-25 @ 4:58 AM

Ignite Modification Date: 2025-12-26 @ 3:58 AM

Study NCT ID: NCT05271318

Status: RECRUITING

Last Update Posted: 2025-11-03

First Post: 2022-02-04

Is NOT Gene Therapy: False

Has Adverse Events: False

Brief Title: Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer.

Sponsor: TILT Biotherapeutics Ltd.

Organization:

Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module